000008432 001__ 8432
000008432 005__ 20240403142203.0
000008432 0247_ $$2DOI$$a10.6083/xp68kh002
000008432 037__ $$aIR
000008432 041__ $$aeng
000008432 245__ $$aDipeptidyl peptidase IV inhibition protects against developmental programming of metabolic diseases in maternal obesity
000008432 260__ $$bOregon Health and Science University
000008432 269__ $$a2020
000008432 336__ $$aAbstract
000008432 520__ $$aThe obesity pandemic produces immense health and economic burdens globally. More than 65% of women entering pregnancy in the US are overweight or obese and maternal obesity leads to the developmental programming of obesity and metabolic diseases in the offspring. Although maternal obesity is recognized as a major driving force behind the obesity pandemic, there are currently no effective therapies to address the detrimental effects of maternal obesity.
000008432 540__ $$fCC BY
000008432 542__ $$fIn copyright - joint owners
000008432 650__ $$aDipeptidyl Peptidase 4$$031123
000008432 650__ $$aObesity$$023118
000008432 650__ $$aDiabetes Mellitus, Type 2$$017675
000008432 650__ $$aObesity, Maternal$$012995
000008432 650__ $$aInflammation$$020800
000008432 650__ $$aPregnancy Complications$$024524
000008432 650__ $$aPregnancy Outcome$$024532
000008432 6531_ $$adevelopmental programming
000008432 7001_ $$aMontaniel, Kim R.$$uOregon Health and Science University$$041354
000008432 7001_ $$aBucher, Matthew$$uOregon Health and Science University$$041354
000008432 7001_ $$aMaloyan, Alina$$uOregon Health and Science University$$041354
000008432 711__ $$aResearch Week$$uOregon Health and Science University$$d2020
000008432 8564_ $$9fdac3261-72cd-42a9-9416-3704596e13b1$$s145820$$uhttps://digitalcollections.ohsu.edu/record/8432/files/ResearchWeek.2020.Montaniel.Kim.pdf
000008432 905__ $$a/rest/prod/xp/68/kh/00/xp68kh002
000008432 980__ $$aResearch Week